James Brumley

James Brumley

James Brumley is a reformed stock broker and former Director of Research for an options-focused newsletter. He’s now primarily a freelance writer, tapping more than a decade’s worth of broad experience to help investors get more out of the market.

With a background in technical analysis as well as fundamental analysis, James writes with a multifaceted philosophy that combines the importance of company performance with the power of stock-trade timing. His commentary is as apt to focus on a chart as it is earnings, as he believes this dual approach is the only way an investor has a shot at consistently beating the market.

James’ work has appeared at several websites, including Street Authority, Motley Fool, Kapitall and Investopedia. When not writing as a journalist, James works on his book explaining his multipronged approach to investing.

Recent Articles

The One Word You Should Know in Biopharma Right Now

Before you become impressed with a particular biopharma company's drug, you'll want to know this detail.

Biopharma’s 6 Biggest Deals: Were They Worth It?

With Amgen set to spend more than $10 billion to buy Onyx, investors are wondering if these super-sized biopharma acquisitions are worth it.

How to Profit From Every Biotech Buyout

Amgen's acquisition of Onyx underscores the fact that one simple biotech investment may also be the best one.

3 More Things Eddie Lampert Just Doesn’t Get About Running Sears

After eight years as majority owner and eight months as CEO, Eddie Lampert still doesn't understand Sears or retailing in general. Here are three of his biggest whiffs.

Retail Stocks Tumble — Time to Buy, or Bail?

Walmart, Macy’s, Target and other retail stocks have given up ground in August. Is it time for investors to go bargain shopping?

Surprise! The Hewlett-Packard Turnaround Is for Real

Few thought struggling Hewlett-Packard would even survive under CEO Meg Whitman, but now believers are stepping into the stock.

Gold’s Red Flag Lies Between the Lines

While physical gold gave gold bugs something to crow about, there's plenty of evidence that institutional money is bailing -- and fast.

Will MannKind’s Luck Change the Second Time Around?

MannKind's diabetes drug, Afrezza, is back in Phase 3 trials and is showing similar promise. But can it clear the hump to approval ... unlike last time?

Should I Buy Priceline? 3 Pros, 3 Cons

The booking site has navigated tough waters masterfully, but will it continue to do so? We look at the pros and cons of Priceline stock.

Dendreon Looks Like a Buy After Meltdown

The Dendreon rags-to-riches-to-rags story saga has a light at the end of the tunnel, but can also teach investors a few valuable big-picture lessons.